BIS Healthcare Analysts in conversation with: Abhishek Goil Founder & CEO ACE Pharmaceuticals, India
BIS Research provides premium market intelligence on deep technologies that have the potential to cause a high level of disruption in the market in the next few years. We excel in conducting market viability analysis for technologies that are still in the nascent stages of their lifecycle.
For each topic that we cover, BIS Research’s analysts interact with dozens of industry experts to scan, analyze, and predict the future of the concerned technology and its market. Our ‘Expert Insight’ series is one such initiative, where we make the industry insights available to senior executives in a short and quick-to-read format.
The hematologic malignancies testing market is expected to witness robust growth attributed to the rise in the incidence of hematologic malignancies such as leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndrome and technological advancements in the field of hematologic malignancies testing and increasing research and development activities
BIS Healthcare Analysts in conversation with: Abhishek Goil Founder & CEO ACE Pharmaceuticals, India
BIS Research provides premium market intelligence on deep technologies that have the potential to cause a high level of disruption in the market in the next few years. We excel in conducting market viability analysis for technologies that are still in the nascent stages of their lifecycle.
For each topic that we cover, BIS Research’s analysts interact with dozens of industry experts to scan, analyze, and predict the future of the concerned technology and its market. Our ‘Expert Insight’ series is one such initiative, where we make the industry insights available to senior executives in a short and quick-to-read format.
The hematologic malignancies testing market is expected to witness robust growth attributed to the rise in the incidence of hematologic malignancies such as leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndrome and technological advancements in the field of hematologic malignancies testing and increasing research and development activities